TCG Crossover Management

Chen Yu founded the firm and leads investment decisions, carrying forward the crossover mandate he built at The Column Group, which he co-founded in 2005. Yu is a physician by training and has overseen the firm's strategy since it was established as a standalone manager in Palo Alto.

TCG Crossover Management was spun out of The Column Group's internal crossover vehicle. The Column Group is a biotechnology-focused venture capital firm also founded by Chen Yu in 2005. The crossover strategy was initially run inside that venture platform before being externalized as an independent manager.

The firm invests across a company's transition from late-stage private funding rounds through IPO and into the public aftermarket. This means writing equity checks in pre-IPO crossover rounds, participating in the IPO allocation, and managing post-IPO positions rather than distributing or selling at the lockup expiry. The mandate concentrates on 10 to 14 core positions.

The firm concentrates heavily on biotechnology, digital health, and health-tech companies, consistent with its lineage inside The Column Group. It has also extended into enterprise technology and select AI/ML platforms, particularly where the technology intersects with drug discovery or clinical development.

The firm focuses on direct equity investments — both private placement rounds in late-stage companies and public-market equity positions in newly listed issuers. There is no public record of TCG Crossover allocating capital to third-party venture funds as a limited partner.